Cytoprotective agents and C. pylori associated acid peptic diseases.
D001729:Bismuth / Q000627:therapeutic use*; D002167:Campylobacter / Q000187:drug effects / Q000302:isolation & purification; D002169:Campylobacter Infections / Q000150:complications* / Q000188:drug therapy / Q000382:microbiology; D005744:Gastric Acid / Q000502:physiology; D005753:Gastric Mucosa / Q000473:pathology*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D013272:Stomach Diseases / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D013392:Sucralfate / Q000627:therapeutic use*
D006635:Histamine H2 Antagonists; D013392:Sucralfate; D001729:Bismuth